Ixekizumab for management of psoriatic arthritis and nonradiographic axial spondyloarthritis
Psoriatic arthritis occurs in up to 30% of people with psoriasis – a promising approach
You will learn:
• The efficacy and safety of ixekizumab in clinical trials of psoriatic arthritis and nonradiographic axial spondyloarthritis.
To access this module, please register or login: